Cargando…

Initiation of L-DOPA Treatment After Detection of Diabetes-Induced Retinal Dysfunction Reverses Retinopathy and Provides Neuroprotection in Rats

PURPOSE: L-DOPA treatment initiated at the start of hyperglycemia preserves retinal and visual function in diabetic rats. Here, we investigated a more clinically relevant treatment strategy in which retinal and visual dysfunction designated the beginning of the therapeutic window for L-DOPA treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Chesler, Kyle, Motz, Cara, Vo, Harrison, Douglass, Amber, Allen, Rachael S., Feola, Andrew J., Pardue, Machelle T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Association for Research in Vision and Ophthalmology 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8054623/
https://www.ncbi.nlm.nih.gov/pubmed/34003986
http://dx.doi.org/10.1167/tvst.10.4.8
_version_ 1783680320579567616
author Chesler, Kyle
Motz, Cara
Vo, Harrison
Douglass, Amber
Allen, Rachael S.
Feola, Andrew J.
Pardue, Machelle T.
author_facet Chesler, Kyle
Motz, Cara
Vo, Harrison
Douglass, Amber
Allen, Rachael S.
Feola, Andrew J.
Pardue, Machelle T.
author_sort Chesler, Kyle
collection PubMed
description PURPOSE: L-DOPA treatment initiated at the start of hyperglycemia preserves retinal and visual function in diabetic rats. Here, we investigated a more clinically relevant treatment strategy in which retinal and visual dysfunction designated the beginning of the therapeutic window for L-DOPA treatment. METHODS: Spatial frequency thresholds using optomotor response and oscillatory potential (OP) delays using electroretinograms were compared at baseline, 3, 6, and 10 weeks after streptozotocin (STZ) between diabetic and control rats. L-DOPA/carbidopa treatment (DOPA) or vehicle was delivered orally 5 days per week beginning at 3 weeks after STZ, when significant retinal and visual deficits were measured. At 10 weeks after STZ, retinas were collected to measure L-DOPA, dopamine, and 3,4-dihydroxyphenylacetic acid (DOPAC) levels using high-performance liquid chromatography. RESULTS: Spatial frequency thresholds decreased at 6 weeks in diabetic vehicle rats (28%), whereas diabetic DOPA rats had stable thresholds (<1%) that maintained to 10 weeks, creating significantly higher thresholds compared with diabetic vehicle rats (P < 0.0001). OP2 implicit times in response to dim, rod-driven stimuli were decreased in diabetic compared with control rats (3 weeks, P < 0.0001; 10 weeks, P < 0.01). With L-DOPA treatment, OP2 implicit times recovered in diabetic rats to be indistinguishable from control rats by 10 weeks after STZ. Rats treated with L-DOPA showed significantly increased retinal L-DOPA (P < 0.001) and dopamine levels (P < 0.05). CONCLUSIONS: L-DOPA treatment started after the detection of retinal and visual dysfunction showed protective effects in diabetic rats. TRANSLATIONAL RELEVANCE: Early retinal functional deficits induced by diabetes can be used to identify an earlier therapeutic window for L-DOPA treatment which protects from further vision loss and restores retinal function.
format Online
Article
Text
id pubmed-8054623
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Association for Research in Vision and Ophthalmology
record_format MEDLINE/PubMed
spelling pubmed-80546232021-05-05 Initiation of L-DOPA Treatment After Detection of Diabetes-Induced Retinal Dysfunction Reverses Retinopathy and Provides Neuroprotection in Rats Chesler, Kyle Motz, Cara Vo, Harrison Douglass, Amber Allen, Rachael S. Feola, Andrew J. Pardue, Machelle T. Transl Vis Sci Technol Article PURPOSE: L-DOPA treatment initiated at the start of hyperglycemia preserves retinal and visual function in diabetic rats. Here, we investigated a more clinically relevant treatment strategy in which retinal and visual dysfunction designated the beginning of the therapeutic window for L-DOPA treatment. METHODS: Spatial frequency thresholds using optomotor response and oscillatory potential (OP) delays using electroretinograms were compared at baseline, 3, 6, and 10 weeks after streptozotocin (STZ) between diabetic and control rats. L-DOPA/carbidopa treatment (DOPA) or vehicle was delivered orally 5 days per week beginning at 3 weeks after STZ, when significant retinal and visual deficits were measured. At 10 weeks after STZ, retinas were collected to measure L-DOPA, dopamine, and 3,4-dihydroxyphenylacetic acid (DOPAC) levels using high-performance liquid chromatography. RESULTS: Spatial frequency thresholds decreased at 6 weeks in diabetic vehicle rats (28%), whereas diabetic DOPA rats had stable thresholds (<1%) that maintained to 10 weeks, creating significantly higher thresholds compared with diabetic vehicle rats (P < 0.0001). OP2 implicit times in response to dim, rod-driven stimuli were decreased in diabetic compared with control rats (3 weeks, P < 0.0001; 10 weeks, P < 0.01). With L-DOPA treatment, OP2 implicit times recovered in diabetic rats to be indistinguishable from control rats by 10 weeks after STZ. Rats treated with L-DOPA showed significantly increased retinal L-DOPA (P < 0.001) and dopamine levels (P < 0.05). CONCLUSIONS: L-DOPA treatment started after the detection of retinal and visual dysfunction showed protective effects in diabetic rats. TRANSLATIONAL RELEVANCE: Early retinal functional deficits induced by diabetes can be used to identify an earlier therapeutic window for L-DOPA treatment which protects from further vision loss and restores retinal function. The Association for Research in Vision and Ophthalmology 2021-04-13 /pmc/articles/PMC8054623/ /pubmed/34003986 http://dx.doi.org/10.1167/tvst.10.4.8 Text en Copyright 2021 The Authors https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License.
spellingShingle Article
Chesler, Kyle
Motz, Cara
Vo, Harrison
Douglass, Amber
Allen, Rachael S.
Feola, Andrew J.
Pardue, Machelle T.
Initiation of L-DOPA Treatment After Detection of Diabetes-Induced Retinal Dysfunction Reverses Retinopathy and Provides Neuroprotection in Rats
title Initiation of L-DOPA Treatment After Detection of Diabetes-Induced Retinal Dysfunction Reverses Retinopathy and Provides Neuroprotection in Rats
title_full Initiation of L-DOPA Treatment After Detection of Diabetes-Induced Retinal Dysfunction Reverses Retinopathy and Provides Neuroprotection in Rats
title_fullStr Initiation of L-DOPA Treatment After Detection of Diabetes-Induced Retinal Dysfunction Reverses Retinopathy and Provides Neuroprotection in Rats
title_full_unstemmed Initiation of L-DOPA Treatment After Detection of Diabetes-Induced Retinal Dysfunction Reverses Retinopathy and Provides Neuroprotection in Rats
title_short Initiation of L-DOPA Treatment After Detection of Diabetes-Induced Retinal Dysfunction Reverses Retinopathy and Provides Neuroprotection in Rats
title_sort initiation of l-dopa treatment after detection of diabetes-induced retinal dysfunction reverses retinopathy and provides neuroprotection in rats
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8054623/
https://www.ncbi.nlm.nih.gov/pubmed/34003986
http://dx.doi.org/10.1167/tvst.10.4.8
work_keys_str_mv AT cheslerkyle initiationofldopatreatmentafterdetectionofdiabetesinducedretinaldysfunctionreversesretinopathyandprovidesneuroprotectioninrats
AT motzcara initiationofldopatreatmentafterdetectionofdiabetesinducedretinaldysfunctionreversesretinopathyandprovidesneuroprotectioninrats
AT voharrison initiationofldopatreatmentafterdetectionofdiabetesinducedretinaldysfunctionreversesretinopathyandprovidesneuroprotectioninrats
AT douglassamber initiationofldopatreatmentafterdetectionofdiabetesinducedretinaldysfunctionreversesretinopathyandprovidesneuroprotectioninrats
AT allenrachaels initiationofldopatreatmentafterdetectionofdiabetesinducedretinaldysfunctionreversesretinopathyandprovidesneuroprotectioninrats
AT feolaandrewj initiationofldopatreatmentafterdetectionofdiabetesinducedretinaldysfunctionreversesretinopathyandprovidesneuroprotectioninrats
AT parduemachellet initiationofldopatreatmentafterdetectionofdiabetesinducedretinaldysfunctionreversesretinopathyandprovidesneuroprotectioninrats